10 Natural product drug discovery from microalgae

Niedermeyer, Timo H. J.; Brönstrup, Mark

doi:10.1515/9783110298321.169

Cited by 17 publications

(19 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MMAE is a synthetic compound derived from dolastatin 10 that was first isolated from the sea hare Dolabella auricularia with described potent antineoplastic activity [85]. The compound was later shown to be produced by the cyanobacteria Symploca hydnoides and Lyngbya majuscula, which are part of the sea hare's diet [86].…”

Section: Approved Natural Compound For Disease Treatmentmentioning

confidence: 99%

Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research

Castro¹,

Preto²,

Vasconcelos³

et al. 2016

CTMC

View full text Add to dashboard Cite

Obesity is a global health threat. OECD reported that more than half (52%) of the adult population in the European Union is overweight or obese. Obesity and obesity-related co-morbidities have deep negative effects on morbidity, mortality, professional and personal quality of life. Healthcare costs represent a negative impact of this disease, with an associated economic cost of 100 billion US$ per year in the United States. The most prescribed drugs for obesity treatment worldwide are orlistat, and phentermine/topiramate extended release, while the major prescribed drug for the same disease in the US are exenatide and dapagliflozin. The so far developed drugs, targeting weight loss, have a long history of malignant secondary effects. There is still a lack of efficient and safe drugs to treat obesity and related metabolic complications since in many cases cure cannot be reached by bariatric surgery or healthy lifestyle habits. Terrestrial and aquatic organisms are a promising source of valuable, bioactive compounds, often with interest for human health. Some of the natural compounds or organisms have been used for centuries by humans as traditional medicine foods. In this review, we give insights into the adipose tissue function and development, and the progress in traditional anti-obesity pharmacotherapy. A major focus is to highlight the state of the art of natural compounds with anti-obesity properties and their potential as candidates for drug development; an overview is given about natural compounds derived from different marine animal sources, cyanobacteria, marine phytoplankton, fungus or plants.

show abstract

Section: Approved Natural Compound For Disease Treatmentmentioning

confidence: 99%

Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research

Castro¹,

Preto²,

Vasconcelos³

et al. 2016

CTMC

View full text Add to dashboard Cite

show abstract

“…range are the cryptophycins from Nostoc [30][31][32]. Their story is told in more detail elsewhere [22].…”

Section: Antifungal Metabolitesmentioning

confidence: 99%

“…In recent years, however, cyanobacteria have gained more attention. They are now recognized as a promising yet underexplored source for novel natural products with potent biological activities, and several reviews covering cyanobacterial metabolites have been published [16][17][18][19][20][21][22][23]. The interest in secondary metabolites from cyanobacteria is rising (l " Fig.…”

mentioning

confidence: 99%

“…Especially the latter compounds are most interesting from a drug development point of view. Although the history of the discovery and development of the dolastatins to the drug substance Brentuximab vedotin, approved in 2011 for the treatment of patients with Hodgkinʼs lymphoma or with systemic anaplastic large cell lymphoma (ALCL), has been rather intricate [22], it can be said that this antibody drug conjugate is the first commercially available drug substance that is based on a cyanobacterial secondary metabolite. Cyanobacterial secondary metabolites exhibit a high chemical diversity [35].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Anti-infective Natural Products from Cyanobacteria

Niedermeyer

2015

Planta Med

Self Cite

View full text Add to dashboard Cite

Cyanobacteria are a promising yet underexplored source for novel natural products with potent biological activities. While predominantly cytotoxic compounds have been isolated from cyanobacteria in the past, there are also a significant number of compounds known that possess anti-infective activities. As the need for novel anti-infective lead compounds is high, this manuscript aims at giving a concise overview on the current knowledge about anti-infective secondary metabolites isolated from cyanobacteria. Antibacterial, antifungal, antiviral, antiprotozoal, and molluscicidal activities are discussed. Covering up to February 2015.

show abstract

“…Cyanobacteria are well recognized producers of bioactive secondary metabolites, and in recent years, several excellent reviews have covered cyanobacterial metabolites (Gademann and Portmann, 2008;Tidgewell, Clark, and Gerwick, 2010;Niedermeyer and Brönstrup, 2012). For more details on the potential pharmaceutical uses of cyanobacterial secondary metabolites see Chapter 4.…”

Section: Secondary Metabolitesmentioning

confidence: 99%